Company / Depreciation & Amortization
Vertex Pharmaceuticals Depreciation & Amortization History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Depreciation & Amortization
$209.8M
FY2025
5-year range
$125.6M / $209.8M
FY2021-FY2025
Trend
+1.3%
vs FY2024
Sector context
#15 of 168
Health Care
What the data says
Among 168 Health Care companies, Vertex Pharmaceuticals is in the bottom 9% for depreciation & amortization. Depreciation & Amortization has increased for 8 consecutive years, from $61M in FY2017 to $210M in FY2025.
Based on SEC 10-K filings.
$210M in FY2025 with a 5-year CAGR of +13.9%. Top quartile in the Health Care sector.
Increased from $181M to $210M over the past 2 years.
Health Care sector context is included.
Depreciation & Amortization over time
Growth rates
- 3-Year CAGR
- +12.3%
- 5-Year CAGR
- +13.9%
- 10-Year CAGR
- -
Sector benchmark
-1.5% below sector average
Key checks
Key Insights
- Vertex Pharmaceuticals's depreciation & amortization has grown for 8 consecutive years.
- 5-year CAGR of +13.9%, indicating consistent growth.
- In FY2025, depreciation & amortization increased 1.3% year-over-year.
- Ranks #15 out of 168 companies in the Health Care sector.
Company context
Key Data Points
- Strong profit margin: 31.4%
- Strong return on equity: 21.2%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Depreciation & AmortizationValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $209.8M | +1.3% |
| FY2024 | $207.2M | +14.3% |
| FY2023 | $181.3M | +22.3% |
| FY2022 | $148.3M | +18.1% |
| FY2021 | $125.6M | +14.7% |
| FY2020 | $109.5M | +2.4% |
| FY2019 | $106.9M | +47.6% |
| FY2018 | $72.4M | +18.0% |
| FY2017 | $61.4M | -0.0% |
| FY2016 | $61.4M | -1.5% |
As of FY2025 · SEC 10-K · Updated Mar 17, 2026